197 related articles for article (PubMed ID: 26384320)
1. Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).
Epeldegui M; Lee JY; Martínez AC; Widney DP; Magpantay LI; Regidor D; Mitsuyasu R; Sparano JA; Ambinder RF; Martínez-Maza O
Clin Cancer Res; 2016 Jan; 22(2):328-36. PubMed ID: 26384320
[TBL] [Abstract][Full Text] [Related]
2. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
[TBL] [Abstract][Full Text] [Related]
3. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
[TBL] [Abstract][Full Text] [Related]
4. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
5. Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study.
Martínez LE; Lensing S; Chang D; Magpantay LI; Mitsuyasu R; Ambinder RF; Sparano JA; Martínez-Maza O; Epeldegui M
Clin Cancer Res; 2021 Aug; 27(16):4642-4651. PubMed ID: 34131000
[TBL] [Abstract][Full Text] [Related]
6. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Barta SK; Xue X; Wang D; Tamari R; Lee JY; Mounier N; Kaplan LD; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Wilson WH; Wyen C; Oriol A; Navarro JT; Dunleavy K; Little RF; Ratner L; Garcia O; Morgades M; Remick SC; Noy A; Sparano JA
Blood; 2013 Nov; 122(19):3251-62. PubMed ID: 24014242
[TBL] [Abstract][Full Text] [Related]
7. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Kaplan LD; Lee JY; Ambinder RF; Sparano JA; Cesarman E; Chadburn A; Levine AM; Scadden DT
Blood; 2005 Sep; 106(5):1538-43. PubMed ID: 15914552
[TBL] [Abstract][Full Text] [Related]
8. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
Sparano JA; Lee JY; Kaplan LD; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R
Haematologica; 2021 Mar; 106(3):730-735. PubMed ID: 32107337
[TBL] [Abstract][Full Text] [Related]
9. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.
Lamar ZS; Fino N; Palmer J; Gruber L; Morris BB; Raetskaya-Solntseva O; Kennedy L; Vaidya R; Hurd D; Zamkoff K
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):76-81. PubMed ID: 26725264
[TBL] [Abstract][Full Text] [Related]
10. AIDS-lymphoma (ARL): one more step along the way.
Levine AM
Blood; 2013 Nov; 122(19):3244-6. PubMed ID: 24203926
[TBL] [Abstract][Full Text] [Related]
11. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Spina M; Simonelli C; Tirelli U
J Clin Oncol; 2007 Feb; 25(6):e7. PubMed ID: 17308261
[No Abstract] [Full Text] [Related]
14. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma.
Patarca R; Freidlander A; Harrington WJ; Cabral L; Byrnes JJ; Fletcher MA
AIDS Res Hum Retroviruses; 1996 May; 12(8):645-9. PubMed ID: 8744574
[No Abstract] [Full Text] [Related]
17. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
[TBL] [Abstract][Full Text] [Related]
18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
20. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]